THE NATIONAL DISCONNECT
Access Has Expanded. Clinical Integration Has Not Kept Pace.
Thirty-eight states currently permit medical cannabis use. Most state-authorized programs continue to operate separately from the systems clinicians, pharmacies, health plans, researchers, and regulators use to manage conventional healthcare.
A System Built for Access. Not Yet Built for Care.
Over the past two decades, state medical cannabis programs have expanded significantly. Millions of patients now participate in state-authorized programs, and the number of licensed dispensaries, registered practitioners, and approved conditions continues to grow.
Yet the infrastructure that supports conventional healthcare has not kept pace. The clinical tools, data systems, interoperability standards, and outcomes-measurement frameworks that practitioners and health systems rely on for every other therapeutic area are largely absent from the medical cannabinoid space.
The result is a fragmented ecosystem. Patients navigate programs without coordinated care. Practitioners make decisions without adequate decision support. Dispensaries operate outside traditional pharmacy and healthcare data systems. Researchers lack standardized outcomes infrastructure. Regulators manage programs without the data exchange capabilities that support other regulated healthcare sectors.
Four Core Gaps
Where the System Falls Short
Fragmented Evidence
Clinical research, program rules, and patient experience exist in separate environments.
The evidence base for medical cannabinoid therapy is growing, but it remains scattered across academic publications, state program databases, product registries, and patient-reported experience platforms. Practitioners seeking to make informed decisions must navigate multiple disconnected sources, none of which are integrated into the clinical workflows and decision-support tools they use for other therapeutic areas.
Key Implications
- Practitioners cannot efficiently access relevant clinical evidence at the point of care
- State program rules and product information are not integrated with clinical guidance
- Patient-reported outcomes are rarely captured in a form that feeds back into clinical learning
- Evidence gaps are difficult to identify and prioritize without a unified view of the landscape
Limited Clinical Visibility
Practitioners often lack visibility into what their patients are using and why.
In conventional pharmacy and therapeutics, practitioners have access to medication histories, dispensing records, and clinical notes that inform care decisions. In the medical cannabinoid space, this visibility is largely absent. Patients may be using cannabinoid products that their primary care providers, specialists, or pharmacists are unaware of, creating gaps in care coordination, drug interaction screening, and outcomes monitoring.
Key Implications
- Cannabinoid use may not be captured in electronic health records or medication histories
- Drug interaction screening cannot occur without visibility into cannabinoid product use
- Care coordination across practitioners is impaired when cannabinoid therapy is invisible to the care team
- Outcomes associated with cannabinoid use cannot be attributed or analyzed without clinical visibility
Disconnected Technology
The systems that manage cannabis programs do not communicate with healthcare infrastructure.
Electronic health records, pharmacy benefit management systems, state seed-to-sale tracking platforms, and dispensary point-of-sale systems were built independently and do not share data standards, interoperability protocols, or integration frameworks. This technological fragmentation means that information generated in one part of the ecosystem cannot flow to where it is needed in another.
Key Implications
- EHR systems have no standard mechanism for receiving or displaying cannabinoid dispensing data
- State seed-to-sale systems track product movement but do not connect to clinical or outcomes data
- Benefit systems cannot evaluate cannabinoid therapy without access to clinical and dispensing data
- Research infrastructure cannot aggregate real-world data without interoperability across systems
Inconsistent Product Context
Patients and practitioners lack a consistent way to connect health considerations with available products.
The regulated cannabis market includes thousands of products with varying cannabinoid profiles, formulations, delivery methods, and potencies. State programs approve products and track inventory, but there is no standardized framework for connecting product-level information with patient health context, clinical evidence, or practitioner guidance. The result is that product selection often occurs without the clinical context that would support more informed decision-making.
Key Implications
- Product information is not standardized across state markets or dispensary platforms
- No consistent mechanism exists to connect patient health context with product selection
- Practitioners cannot easily evaluate product options relative to clinical evidence or patient history
- Patients navigating product selection often do so without adequate clinical guidance or context
RESCHEDULING AND THE EMERGING MEDICAL MODEL
Rescheduling Could Change the Federal Framework. But It Will Not Automatically Connect the System.
The federal process considering the movement of marijuana from Schedule I to Schedule III has intensified questions about research, medical use, practitioner education, regulatory oversight, and potential reimbursement pathways.
Rescheduling alone would not transform state cannabis programs into a conventional healthcare model. It could, however, make the absence of shared clinical and data infrastructure more visible and more urgent. The questions that rescheduling raises about practitioner education, evidence standards, regulatory oversight, and reimbursement pathways all depend on infrastructure that does not yet exist.
Today
- State-by-state medical programs
- Disconnected clinical and retail data
- Limited EHR visibility
- Variable practitioner education
- Inconsistent product-level information
- Few standardized outcome-measurement pathways
Emerging Transition
- Expanded research possibilities
- Increased demand for clinical evidence
- Greater attention to practitioner decision support
- New regulatory and reimbursement questions
- Need for interoperable data standards
- Demand for real-world outcome measurement
The Infrastructure Gap
- Clinical decision intelligence
- Patient-context integration
- Product and inventory intelligence
- Benefit-system connectivity
- Regulatory data exchange
- Longitudinal outcomes analysis
CCDI™ Is Being Built to Address These Gaps.
We are developing the clinical decision-intelligence infrastructure needed to connect evidence, patient context, product information, and real-world outcomes across the medical cannabinoid ecosystem. We are seeking research, technology, healthcare, and policy collaborators.